Market access risk in endocrinology and metabolism

No field has tested the limits of what health systems will pay for as sharply as this one. The new obesity and diabetes medicines work in a way that was unimaginable a decade ago, and they are wanted by more people than any health system can afford to treat at launch prices — so the reimbursement question has become a question of who, how long, and at what point the budget says no. Beside that debate sits a quieter one: rare hormonal and bone disorders, growth conditions of childhood, and lifelong replacement therapies, each judged on a few hundred patients and decades of treatment. This page brings together MARA's independent assessments of reimbursement risk across the field; obesity has its own deep-dive page beneath it.

What payers ask in endocrinology and metabolism

Is weight loss a benefit payers pay for? Many health systems have historically treated obesity as a lifestyle matter rather than a disease, and some still exclude weight-loss medicines from coverage altogether. Where they do pay, they ask for the outcomes behind the kilograms — fewer heart attacks, less diabetes, less joint surgery — and reimburse the groups where that evidence exists.

How many people, for how long, at what price? The eligible population for an obesity or diabetes medicine can be a tenth of the adult population. Payers answer that arithmetic with eligibility thresholds, prior authorisation, limited treatment periods and price negotiations harder than anywhere else in medicine — the budget decides before the evidence does.

What happens when treatment stops? Weight returns when the medicine stops, and growth or hormone disorders need treatment for years. Payers want stopping rules, maintenance data and evidence of persistence, because a drug that must be taken for life is priced as one — and a drug that patients abandon within a year is paid for without the benefit.

For the rare conditions, what is the comparison? Rare endocrine diseases often have no treated comparator, only the natural course of the disease. Payers ask how growth, bone, or hormone levels would have moved without the drug, how long the follow-up runs, and whether the measured change is one the patient feels — the standard questions of orphan reimbursement, applied to children.

The MARA record in endocrinology and metabolism

Endocrinology and metabolism holds more than twenty dated assessments in the MARA catalogue: the obesity and type 2 diabetes medicines in their injectable and oral forms, growth hormone replacement in children, acromegaly, achondroplasia, rare phosphate and thyroid-hormone disorders, and osteoporosis after the menopause. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Deep-dive: Market access risk in obesity

Current assessments (20)

Earlier assessments (each replaced by a newer version)

Selected commentary

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.